Company: DMAAR
Filing Date: 2025-01-14
Form Type: POS AM
Source: 0001213900-25-003137
Chunk: 288

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-01-14
Form: POS AM
Chunk 288
---
 Sponsor, resulting in a balance of approximately $185,000 due to the Sponsor as of June30, 2024, which is accounted for as part of the promissory note amount on the balance sheet. During the period from May23, 2024 (inception) through September30, 2024, the Company repaid approximately $1,200,000 of the balance due to the Sponsor related to investments it had received on behalf of the Sponsor, resulting in a balance of approximately $500,000 due to the Sponsor as of September30, 2024, which is accounted for as part of the promissory note amount on the balance sheet. As of September30, 2024 and June 30, 2024, there were $552,015 and $210,090, respectively, outstanding under the Promissory Note. Advisory services The Company received advisory services from an uncompensated related party advisor, husband to the CEO of the Company. The role of such advisor is to assist in the day to day transactions of the Company. Related Party Loans In order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans, but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination, without interest, or, at the lender’s discretion, up to $1,500,000 of such Working Capital Loans may be convertible into units of the post -BusinessCombination entity at a price of $10.00 per unit. The units would be identical to the Private Placement Units. As of September30, 2024 and June 30, 2024, no working capital loans were outstanding. NOTE 6 — COMMITMENTS AND CONTINGENCIES